Perspective Therapeutics
CATX | AMEX
$0.94
$0.00 (-0.33%)
At close: Nov 16, 2026, 3:59 PM ET
$0.96
+$0.02 (+1.79%)
After-hours:
Nov 16, 2026, 7:18 PM ET
Perspective Therapeutics Company Profile
Company profile explainedCompany Profile
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Key Executives
| Name | Position |
|---|---|
| Johan Spoor | Chief Executive Officer & Director |
| Andrew Bright | Executive Vice President of Brachytherapy |
| Annie J. Cheng | Vice President of Investor Relations |
| Chris Nenno | General Counsel & Corporate Secretary |
| Joel David Sendek | CFO & Principal Financial Officer |
| Jonathan R. Hunt | Chief Accounting Officer |
| Markus Puhlmann | Chief Medical Officer |
| Michael K. Schultz | Co-Founder & Senior Scientific Advisor |
| Paul Lyne | Chief Science Officer |
| Shane Cobb | Executive Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | 8-K | Current Report |
| Oct 08, 2026 | 8-K | Current Report |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 23, 2026 | SC 13D/A | [Amend] Filing |
| Sep 14, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | SC 13D/A | [Amend] Filing |
Perspective Therapeutics
| Country | United States |
| IPO Date | Nov 10, 2005 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 165 |
| CEO | Johan Spoor |
Contact Details
2401 Elliott Avenue Seattle,
Washington 98121 United States
Stock Details
| Ticker Symbol | CATX |
| Exchange | AMEX |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0000728387 |
| CUSIP Number | 46489V302 |
| ISIN Number | US46489V3024 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove CATX